How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept

Efficacy and safety of nanomedicines based on polymeric (bio)materials will benefit from a rational implementation of a Safe-by-Design (SbD) approach throughout their development. In order to achieve this goal, however, a standardization of preparation and characterization methods and their accurate...

Full description

Bibliographic Details
Main Authors:	Cíntia Marques, Claudia Som, Mélanie Schmutz, Olga Borges, Gerrit Borchard
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-03-01
Series:	Frontiers in Bioengineering and Biotechnology
Subjects:	safe by design polymeric drug carriers chitosan insulin protein drug delivery
Online Access:	https://www.frontiersin.org/article/10.3389/fbioe.2020.00165/full

id	doaj-94c073edb12a48dba1bd59668d5e4423
record_format	Article
spelling	doaj-94c073edb12a48dba1bd59668d5e44232020-11-24T21:46:30ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852020-03-01810.3389/fbioe.2020.00165502562How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design ConceptCíntia Marques0Cíntia Marques1Claudia Som2Mélanie Schmutz3Olga Borges4Olga Borges5Gerrit Borchard6Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandFaculty of Pharmacy, University of Coimbra, Coimbra, PortugalEmpa, Swiss Federal Laboratories for Materials Science and Technology, Technology and Society Laboratory, St. Gallen, SwitzerlandEmpa, Swiss Federal Laboratories for Materials Science and Technology, Technology and Society Laboratory, St. Gallen, SwitzerlandFaculty of Pharmacy, University of Coimbra, Coimbra, PortugalCenter for Neuroscience and Cell Biology, University of Coimbra, Coimbra, PortugalInstitute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandEfficacy and safety of nanomedicines based on polymeric (bio)materials will benefit from a rational implementation of a Safe-by-Design (SbD) approach throughout their development. In order to achieve this goal, however, a standardization of preparation and characterization methods and their accurate reporting is needed. Focusing on the example of chitosan, a biopolymer derived from chitin and frequently used in drug and vaccine delivery vector preparation, this review discusses the challenges still to be met and overcome prior to a successful implementation of the SbD approach to the preparation of chitosan-based protein drug delivery systems.https://www.frontiersin.org/article/10.3389/fbioe.2020.00165/fullsafe by designpolymeric drug carrierschitosaninsulinprotein drug delivery
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Cíntia Marques Cíntia Marques Claudia Som Mélanie Schmutz Olga Borges Olga Borges Gerrit Borchard
spellingShingle	Cíntia Marques Cíntia Marques Claudia Som Mélanie Schmutz Olga Borges Olga Borges Gerrit Borchard How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept Frontiers in Bioengineering and Biotechnology safe by design polymeric drug carriers chitosan insulin protein drug delivery
author_facet	Cíntia Marques Cíntia Marques Claudia Som Mélanie Schmutz Olga Borges Olga Borges Gerrit Borchard
author_sort	Cíntia Marques
title	How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept
title_short	How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept
title_full	How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept
title_fullStr	How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept
title_full_unstemmed	How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept
title_sort	how the lack of chitosan characterization precludes implementation of the safe-by-design concept
publisher	Frontiers Media S.A.
series	Frontiers in Bioengineering and Biotechnology
issn	2296-4185
publishDate	2020-03-01
description	Efficacy and safety of nanomedicines based on polymeric (bio)materials will benefit from a rational implementation of a Safe-by-Design (SbD) approach throughout their development. In order to achieve this goal, however, a standardization of preparation and characterization methods and their accurate reporting is needed. Focusing on the example of chitosan, a biopolymer derived from chitin and frequently used in drug and vaccine delivery vector preparation, this review discusses the challenges still to be met and overcome prior to a successful implementation of the SbD approach to the preparation of chitosan-based protein drug delivery systems.
topic	safe by design polymeric drug carriers chitosan insulin protein drug delivery
url	https://www.frontiersin.org/article/10.3389/fbioe.2020.00165/full
work_keys_str_mv	AT cintiamarques howthelackofchitosancharacterizationprecludesimplementationofthesafebydesignconcept AT cintiamarques howthelackofchitosancharacterizationprecludesimplementationofthesafebydesignconcept AT claudiasom howthelackofchitosancharacterizationprecludesimplementationofthesafebydesignconcept AT melanieschmutz howthelackofchitosancharacterizationprecludesimplementationofthesafebydesignconcept AT olgaborges howthelackofchitosancharacterizationprecludesimplementationofthesafebydesignconcept AT olgaborges howthelackofchitosancharacterizationprecludesimplementationofthesafebydesignconcept AT gerritborchard howthelackofchitosancharacterizationprecludesimplementationofthesafebydesignconcept
_version_	1725901821272129536

How the Lack of Chitosan Characterization Precludes Implementation of the Safe-by-Design Concept

Similar Items